Eli Lilly’s ongoing platform technology evaluation with Peptron, initially signed in October 2024 and extended in December 2025 through the October 7, 2026 deadline, has yet to produce a commercial licensing or technology-transfer agreement for the SmartDepot long-acting microsphere platform. Recent reporting highlights Lilly’s accelerated push into oral GLP-1 candidates such as orforglipron, which may reduce urgency for injectable sustained-release formulations. No new milestones or binding commitments have surfaced since the extension, leaving traders to price in the risk that additional in-vivo studies and internal reviews will push any final deal past the resolution date.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
NUEVO
7 oct 2026
NUEVO
NUEVO
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation with Peptron, initially signed in October 2024 and extended in December 2025 through the October 7, 2026 deadline, has yet to produce a commercial licensing or technology-transfer agreement for the SmartDepot long-acting microsphere platform. Recent reporting highlights Lilly’s accelerated push into oral GLP-1 candidates such as orforglipron, which may reduce urgency for injectable sustained-release formulations. No new milestones or binding commitments have surfaced since the extension, leaving traders to price in the risk that additional in-vivo studies and internal reviews will push any final deal past the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$8,224Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation with Peptron, initially signed in October 2024 and extended in December 2025 through the October 7, 2026 deadline, has yet to produce a commercial licensing or technology-transfer agreement for the SmartDepot long-acting microsphere platform. Recent reporting highlights Lilly’s accelerated push into oral GLP-1 candidates such as orforglipron, which may reduce urgency for injectable sustained-release formulations. No new milestones or binding commitments have surfaced since the extension, leaving traders to price in the risk that additional in-vivo studies and internal reviews will push any final deal past the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$8,224Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing platform technology evaluation with Peptron, initially signed in October 2024 and extended in December 2025 through the October 7, 2026 deadline, has yet to produce a commercial licensing or technology-transfer agreement for the SmartDepot long-acting microsphere platform. Recent reporting highlights Lilly’s accelerated push into oral GLP-1 candidates such as orforglipron, which may reduce urgency for injectable sustained-release formulations. No new milestones or binding commitments have surfaced since the extension, leaving traders to price in the risk that additional in-vivo studies and internal reviews will push any final deal past the resolution date.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes